Samaratunga, Hemamali MBBS, FRCPA*,†; Egevad, Lars MD, PhD‡; Yaxley, John W. MBChB, FRACS†,§; Johannsen, Shulammite MSc*; Le Fevre, Ian K. MBBS, FRCPA*; Perry-Keene, Joanna L. MBBS, FRCPA*; Gianduzzo, Troy MBBS,FRACS†,§; Chabert, Charles MBBS, FRACS§; Coughlin, Gregory MBBS, FRACS§; Parkinson, Robert MBBS, FRACS§; Kua, Boon MBBS, FRACS§; Yaxley, William MBBS∥; Delahunt, Brett MD, FRCPA*,¶
*Aquesta Uropathology
†University of Queensland
§Department of Pathology and Molecular Medicine, Wesley Hospital, Brisbane
∥Redcliffe Hospital, Redcliffe, QLD, Australia
‡Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
¶Malaghan Institute of Medical Research, Wellington, New Zealand
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Brett Delahunt, MD, FRCPA, Aquesta Uropathology, 21 Lissner Street, Toowong, QLD 4066, Australia (e-mail: [email protected]).